In the Cartitude 1 trial, the strongest predictor of long-term remission with Siltacel was a lower burden of disease (measured by bone marrow percentage and soluble BCMA levels), rather than the number of prior treatments. This implies using CAR-T therapy earlier in the disease course is more effective.

Clinicians must weigh the immediate benefit of using community-accessible belantumab against the risk of reducing the efficacy of future BCMA-targeted therapies like CAR-T or bispecifics. This decision hinges on a patient's ability to travel and access advanced care, creating a complex treatment sequencing challenge.

Data from J&J's Majestic 3 trial suggests its off-the-shelf bispecific combination could rival the efficacy of its own blockbuster CAR-T, Carvykti. This sets up an internal competition where a more accessible therapy could challenge a complex, personalized one in earlier lines of treatment.

Despite excitement for in-vivo CAR-Ts, the high response rates and multi-year survival of current autologous therapies create a significant competitive moat. New modalities must not only match this efficacy but also prove long-term durability, a high bar that insulates incumbents in indications like multiple myeloma for the foreseeable future.

Despite the individual high efficacy of both BCMA-directed therapies and anti-CD38 antibodies, there is significant clinical concern about combining them. The potential for compounded immunosuppression and severe infection risk is a major barrier shaping clinical trial design and favoring sequential use over concurrent combination.

Unlike older IMiDs where T-cell effects are secondary, CELMoDs have a powerful, independent pro-T-cell mechanism. This dual action is so significant that in the future, CELMoDs will be prescribed not just for their direct anti-myeloma effects, but specifically to enhance the efficacy of T-cell therapies like CAR-T and bispecific antibodies.

Using a BCMA bispecific antibody first can exhaust a patient's T-cells or cause tumors to lose the BCMA target, rendering a subsequent BCMA-targeted CAR-T therapy ineffective. The optimal sequence is CAR-T first, which preserves T-cell function and BCMA expression, leaving bispecifics as a viable later-line option.

A key driver of Legend Biotech's $2 billion revenue run rate is its successful regulatory strategy. By getting its CAR T therapy, CARVICTI, approved as a second-line treatment in both the US and Europe, the company significantly expanded its addressable patient market beyond last-resort cases.

CARTITUDE-IV trial data challenges the idea of reserving CAR-T therapy for high-risk myeloma. In early relapse, standard-risk patients treated with siltacel had a longer progression-free survival than even high-risk patients on the same therapy. This suggests standard-risk patients may gain the most relative benefit from earlier CAR-T intervention compared to standard of care.